Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study'' by Calvo-Aranda et al

Ann Rheum Dis. 2023 Feb;82(2):e35. doi: 10.1136/annrheumdis-2020-219534. Epub 2020 Dec 14.
No abstract available

Keywords: epidemiology; glucocorticoids; interleukin 1 receptor antagonist protein.

MeSH terms

  • COVID-19 Drug Treatment
  • COVID-19*
  • Cytokine Release Syndrome / drug therapy
  • Glucocorticoids / therapeutic use
  • Humans
  • Treatment Outcome

Substances

  • Glucocorticoids
  • tocilizumab